Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.
Research Site, Cluj Napoca, Romania
ICON-Salt Lake City, Salt Lake City, Utah, United States
Celerion, Tempe, Arizona, United States
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
University of Alabama at Birmingham Children's of Alabama, Birmingham, Alabama, United States
Children's National Medical Center, Washington, District of Columbia, United States
Johns Hopkins All Children's, Saint Petersburg, Florida, United States
Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States
ICON (Site 0001), Lenexa, Kansas, United States
Yale New Haven Health, New Haven, Connecticut, United States
Yale New Haven Hospital, New Haven, Connecticut, United States
Celerion ( Site 0001), Lincoln, Nebraska, United States
Peking University Third Hospital, Beijing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.